Skip to content
Clinicians
Member Value Tools
Practice Insights
Verana Trial Connect
Quality Measures Dashboards
MIPS Advisory Offerings
Manual Data Entry
Verana Research Network
Evolve Registry
Life Sciences
Clinical Development
HEOR & Medical Affairs
Commercialization
Research
Partners
Societies
CROs
Technology and Data
Company
About
Team
Press
Blog
Careers
Privacy
Patient Privacy
Privacy Policy
Products
Ophthalmology Qdata
Anti-VEGF Market Tracker
Diabetic Retinopathy
Dry Eye Disease
Cataracts
Geographic Atrophy
Glaucoma
Neovascular AMD
Retinitis Pigmentosa
Thyroid Eye Disease
Uveitic Macular Edema
Qdata Explorer
Other Ophthalmic Conditions
Neurology Qdata
Multiple Sclerosis
Parkinson’s Disease
Spinal Muscular Atrophy
Other Neurological Conditions
Urology Qdata
Benign Prostatic Hyperplasia
Bladder Cancer
Prostate Cancer
Other Urological Conditions
Clinical Trials
Site Explorer
Solutions
Clinical Research
Trial Design
Protocol Optimization & Site Selection
Patient Recruitment
Prospective Evidence Generation (PEG)
Market Insights
Market Tracking
Brand Switching
Prescriber Mapping
RWE Studies
Patient Segmentation
Safety Studies
Natural History of Disease / Disease Progression
Comparative Effectiveness
Treatment Patterns & Outcomes
Healthcare Resource Utilization (HCRU) Cost
Phase IV Studies / Surveillance
Contact Us
Clinicians
Member Value Tools
Practice Insights
Verana Trial Connect
Quality Measures Dashboards
MIPS Advisory Offerings
Manual Data Entry
Verana Research Network
Evolve Registry
Life Sciences
Clinical Development
HEOR & Medical Affairs
Commercialization
Research
Partners
Societies
CROs
Technology and Data
Company
About
Team
Press
Blog
Careers
Privacy
Patient Privacy
Privacy Policy
Products
Ophthalmology Qdata
Anti-VEGF Market Tracker
Diabetic Retinopathy
Dry Eye Disease
Cataracts
Geographic Atrophy
Glaucoma
Neovascular AMD
Retinitis Pigmentosa
Thyroid Eye Disease
Uveitic Macular Edema
Qdata Explorer
Other Ophthalmic Conditions
Neurology Qdata
Multiple Sclerosis
Parkinson’s Disease
Spinal Muscular Atrophy
Other Neurological Conditions
Urology Qdata
Benign Prostatic Hyperplasia
Bladder Cancer
Prostate Cancer
Other Urological Conditions
Clinical Trials
Site Explorer
Solutions
Clinical Research
Trial Design
Protocol Optimization & Site Selection
Patient Recruitment
Prospective Evidence Generation (PEG)
Market Insights
Market Tracking
Brand Switching
Prescriber Mapping
RWE Studies
Patient Segmentation
Safety Studies
Natural History of Disease / Disease Progression
Comparative Effectiveness
Treatment Patterns & Outcomes
Healthcare Resource Utilization (HCRU) Cost
Phase IV Studies / Surveillance
Contact Us
Research
SUO 2025: Real-world Outcomes in Patients with BCG-unresponsive, High-risk, Non-muscle Invasive Bladder Cancer with Carcinoma in Situ – A Chart Review Study in the American Urological Association’s Quality Registry
December 16, 2025
Read More...
Standalone Canaloplasty and Trabeculotomy Using the OMNI Surgical System: A Subgroup Analysis from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight)
November 3, 2025
Read More...
Contemporary Trends of Benign Prostatic Hyperplasia Procedures in the AUA Quality Registry: Are We Moving the Needle Toward More Minimally Invasive Treatments?
May 29, 2025
Read More...
A Multifaceted Assessment of Benign Prostatic Hyperplasia Practice and AUA Guideline Adherence
May 29, 2025
Read More...
Who Progresses to Third-Line Therapies for Overactive Bladder? Trends From the AQUA Registry
May 29, 2025
Read More...
Choice of First Medication Prescribed For Overactive Bladder Changes With Time: Trends From The AUA AQUA Registry
May 29, 2025
Read More...
Factors Influencing Medication Selection for Management of Overactive Bladder: Trends and Insights From AUA Quality Registry
May 29, 2025
Read More...
Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US
May 29, 2025
Read More...
Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration
May 21, 2025
Read More...
How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema”
December 13, 2024
Read More...
1
2
3
…
15
Next »
